Helix BioPharma (TSE:HBP) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Helix BioPharma Corp. has entered into a non-binding letter of intent to acquire the oncology assets of Laevoroc Group, potentially enhancing their immuno-oncology portfolio. The acquisition includes a novel oral chemotherapy formulation and a preclinical immune checkpoint inhibitor, which could simplify cancer treatment and offer new hope for leukemia patients.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money